Regenerative therapy after cancer: what are the risks?

Area of Science:

• Regenerative medicine
• Oncology
• Tissue engineering

Background:

• Reconstruction after cancer surgery, particularly postmastectomy breast reconstruction, often requires tissue regeneration.
• Autologous fat transfer for breast reconstruction faces challenges with graft volume retention.
• Mesenchymal stem cells (MSCs) show potential for enhancing graft vascularization.

Purpose of the Study:

• To review the interactions between tumor cells and MSCs in regenerative conditions.
• To assess the potential risks of promoting cancer recurrence with regenerative therapies.
• To inform the timing of engineered tissue reconstruction relative to cancer treatment.

Main Methods:

• Review of coculture models examining tumor/MSC interactions.
• Analysis of animal models simulating regenerative tissue environments.
• Evaluation of evidence from case reports, cell lines, and clinical isolates.

Main Results:

• Regenerating tissue appears to promote the growth of active, high-grade tumors.
• Dormant cancer cells do not exhibit activation by wound healing and regeneration signals.
• Evidence suggests a differential effect based on tumor activity status.

Conclusions:

• Engineered tissue reconstruction involving regenerative therapies may increase the risk of recurrence for active cancers.
• Dormant cancer cells are less likely to be affected by regenerative processes.
• Tissue reconstruction should be postponed until cancer remission is definitively established.